JANÍKOVÁ, Andrea, Zbyněk BORTLÍČEK, Vit CAMPR, Natasa KOPALOVA, Katerina BENESOVA, David BELADA, Vit PROCHAZKA, Robert PYTLIK, Samuel VOKURKA, Jan PIRNOS, Juraj DURAS, Heidi MOCIKOVA, Jiří MAYER a Marek TRNENY. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of earlystage follicular lymphoma: is it time to change the standard strategy? Leukemia & Lymphoma. London: Informa Healthcare, 2015, roč. 56, č. 8, s. 2350-2356. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2014.990010. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1318860, author = {Janíková, Andrea and Bortlíček, Zbyněk and Campr, Vit and Kopalova, Natasa and Benesova, Katerina and Belada, David and Prochazka, Vit and Pytlik, Robert and Vokurka, Samuel and Pirnos, Jan and Duras, Juraj and Mocikova, Heidi and Mayer, Jiří and Trneny, Marek}, article_location = {London}, article_number = {8}, doi = {http://dx.doi.org/10.3109/10428194.2014.990010}, keywords = {Follicular lymphoma; rituximab; radiotherapy}, language = {eng}, issn = {1042-8194}, journal = {Leukemia & Lymphoma}, title = {Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of earlystage follicular lymphoma: is it time to change the standard strategy?}, volume = {56}, year = {2015} }
TY - JOUR ID - 1318860 AU - Janíková, Andrea - Bortlíček, Zbyněk - Campr, Vit - Kopalova, Natasa - Benesova, Katerina - Belada, David - Prochazka, Vit - Pytlik, Robert - Vokurka, Samuel - Pirnos, Jan - Duras, Juraj - Mocikova, Heidi - Mayer, Jiří - Trneny, Marek PY - 2015 TI - Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of earlystage follicular lymphoma: is it time to change the standard strategy? JF - Leukemia & Lymphoma VL - 56 IS - 8 SP - 2350-2356 EP - 2350-2356 PB - Informa Healthcare SN - 10428194 KW - Follicular lymphoma KW - rituximab KW - radiotherapy N2 - Early-stage follicular lymphoma (FL) has traditionally been treated with involved-fi eld radiotherapy (RT). Rituximab (R) is a low-toxic, effi cient systemic therapy for FL, but there are no data about its clinical impact in early FL. We retrospectively analyzed 93 patients with stage I – II indolent FL treated with RT (n=65) or RT + R (n=14) or R alone (n=14). Median follow-up was 5.0 years for patients with RT, 2.8 years for the RT + R subgroup and 2.5 years for patients treated with R. The complete response rate was 92%, 100% and 86% (not signifi cant) and the median PFS was 3.3 years, not reached and 4.9 years (p=0.035) for the RT, RT + R and R arms, with no impact on overall survival. R combined with RT seems to give better results in terms of global FL control, but longer follow-up and prospective comparison are needed to verify these results. ER -
JANÍKOVÁ, Andrea, Zbyněk BORTLÍČEK, Vit CAMPR, Natasa KOPALOVA, Katerina BENESOVA, David BELADA, Vit PROCHAZKA, Robert PYTLIK, Samuel VOKURKA, Jan PIRNOS, Juraj DURAS, Heidi MOCIKOVA, Jiří MAYER a Marek TRNENY. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of earlystage follicular lymphoma: is it time to change the standard strategy? \textit{Leukemia \&{} Lymphoma}. London: Informa Healthcare, 2015, roč.~56, č.~8, s.~2350-2356. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2014.990010.
|